Get the Stockscreener App
5.77
5.68%
0.31
After Hours:
5.75
-0.02
-0.35%
Mind Medicine Inc stock is traded at $5.77, with a volume of 1.17M.
It is up +5.68% in the last 24 hours and down -10.82% over the past month.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
See More
Previous Close:
$5.46
Open:
$5.46
24h Volume:
1.17M
Relative Volume:
0.63
Market Cap:
$418.29M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-2.3551
EPS:
-2.45
Net Cash Flow:
$-64.37M
1W Performance:
+12.26%
1M Performance:
-10.82%
6M Performance:
-10.12%
1Y Performance:
-39.45%
1-Day Range:
$5.45
$5.8394
1-Week Range:
$5.0539
$5.85
52-Week Range:
$4.70
$10.44
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
5.77 | 418.29M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
Broadway Gold Mining : MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations - marketscreener.com
MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder - TipRanks
Oppenheimer maintains MindMed stock Outperform with $20 target By Investing.com - Investing.com India
MindMed launches phase 3 LSD study for depression By Investing.com - Investing.com Nigeria
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - GuruFocus
MindMed launches phase 3 LSD study for depression - Investing.com Australia
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of - GuruFocus
Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd) - marketscreener.com
MindMed Appoints Schond L. Greenway as Chief Financial Officer - MarketScreener
MNMD stock touches 52-week low at $5.03 amid market challenges - Investing.com India
Long Term Trading Analysis for (MNMD) - news.stocktradersdaily.com
MNMD stock touches 52-week low at $5.03 amid market challenges By Investing.com - Investing.com South Africa
MNMD Stock Forecast From 2025 To 2040 - Exla Resources
Mind Medicine CEO Robert Barrow sells shares worth $142,941 By Investing.com - Investing.com Canada
MindMed Advances Clinical Programs with Strong Financial Backing - TipRanks
Mind Medicine CEO Robert Barrow sells shares worth $142,941 - Investing.com India
MindMed Announces New Employee Inducement Grants - Business Wire
MindMed Strengthens Brain Health Pipeline with Key Technical Talent Acquisition - Stock Titan
Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR
MindMed appoints new Chief Commercial Officer By Investing.com - Investing.com South Africa
MindMed Appoints Matt Wiley as Chief Commercial Officer - Quantisnow
MindMed appoints new Chief Commercial Officer - Investing.com
MindMed Taps Former Jazz Pharma Executive to Lead MM120 Anxiety Drug Launch - Stock Titan
MindMed’s SWOT analysis: psychedelic stock’s journey through mental health market - Investing.com
MindMed at Leerink’s Global Healthcare Conference: Strategic Insights on Psychedelics - Investing.com India
What is HC Wainwright’s Estimate for MNMD FY2029 Earnings? - Defense World
Robert W. Baird Cuts Mind Medicine (MindMed) (NASDAQ:MNMD) Price Target to $16.00 - Defense World
Mind Medicine (MindMed)’s (MNMD) Buy Rating Reiterated at HC Wainwright - Defense World
Mind Medicine’s (MNMD) Recent Achievements Boosting Stock - Markets Insider
Rhumbline Advisers Buys 4,868 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Oppenheimer & Co. Inc. Grows Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Sanctuary Advisors LLC Lowers Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
H.C. Wainwright maintains MindMed stock Buy rating, $55 target - Investing.com India
Mind Medicine’s Promising Future: Buy Rating Backed by Strong Phase 3 Prospects and Financial Position - TipRanks
Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com
Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
MindMed Advances Clinical Trials and Strengthens Financial Position - TipRanks
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months - MSN
MindMed posts strong cash position, progress on LSD treatment - Green Market Report
Earnings call transcript: MindMed misses Q4 2024 EPS forecast, stock slides - Investing.com
Mind Medicine (MindMed) Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Mind Medicine (MindMed) Inc. SEC 10-K Report - TradingView
Mind Medicine reports Q4 EPS (41c), consensus (28c) - TipRanks
MIND MEDICINE Earnings Results: $MNMD Reports Quarterly Earnings - Nasdaq
Mind Medicine (MindMed) Inc. Loss At -$34.74 Mln In Q4 - Nasdaq
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates - Joplin Globe
MindMed to Present at Leerink’s Global Healthcare Conference 2025 - TipRanks
Can MindMed's Conference Appearance Signal New Brain Health Breakthroughs? - Stock Titan
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):